Using a paired-sampling approach, in which BE lesions and esophageal adenocarcinoma from the same patient were subjected to whole exome sequencing, it was shown that premalignant and malignant lesions from an individual patient shared a specific TP53 mutation more often than other tumor suppressors [19]. This evidence concerns the gene TP53 and esophageal adenocarcinoma.